{"id":"NCT00296517","sponsor":"GlaxoSmithKline","briefTitle":"Study In Patients With Depression Not Responding to Selective Serotonin Re-uptake Inhibitors","officialTitle":"Clinical Evaluation of 323U66 SR in Patients With Depression - Placebo-controlled, Double-blind, Comparative Study in Patients With Depression Who Did Not Respond Sufficiently to Selective Serotonin Re-uptake Inhibitors","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2006-01-19","primaryCompletion":"2008-03-28","completion":"2008-03-28","firstPosted":"2006-02-27","resultsPosted":"2009-07-16","lastUpdate":"2019-12-04"},"enrollment":325,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Depressive Disorder"],"interventions":[{"type":"DRUG","name":"323U66 (Bupropion Hydrochloride Sustained Release)","otherNames":[]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"Placebo","type":"PLACEBO_COMPARATOR"},{"label":"Bupropion SR","type":"EXPERIMENTAL"}],"summary":"This study is designed to evaluate the efficacy and safety in depressive patients who did not respond sufficiently to selective serotonin re-uptake inhibitors (SSRI).","primaryOutcome":{"measure":"Change From Baseline in the Hamilton Depression Scale (HAM-D 17 Items) Total Score","timeFrame":"Baseline and Week 12","effectByArm":[{"arm":"Placebo","deltaMin":19.8,"sd":4.34},{"arm":"Bupropion SR","deltaMin":19.4,"sd":4.39}],"pValues":[{"comp":"OG000 vs OG001","p":"0.805"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":10,"exclusionCount":25},"locations":{"siteCount":62,"countries":["Japan"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0},"commonTop":["Nasopharyngitis","Nausea","Depression","Dizziness","Headache"]}}